EVA Air Cargo - Delivering Freshness
Cytiva Let's Talk

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

Breakthrough Taletrectinib Developed for Non-Small Cell Lung Cancer

AnHeart Therapeutics discovered breakthrough investigational ROS-1 inhibitor taletrectinib for the treatment of patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib is applicable for patients with ROS1 tyrosine kinase inhibitor...

Breakthrough Gedatolisib Therapy Discovered for the Treatment of Metastatic Breast Cancer

Celcuity Inc discovered Gedatolisib new therapy for the treatment of HR+/HER2- Metastatic Breast Cancer. Gedatolisib, the first-in-class pan-PI3K/mTOR inhibitor, is applicable for patients progressed with CDK4/6 therapy and a non-steroidal aromatase inhibitor....

Novel Talquetamab Developed for Relapsed or Refractory Multiple Myeloma

Janssen Pharmaceutical Companies developed novel talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma. Talquetamab is a potential first-in-class, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells...

ENHERTU® Breakthrough Therapy Discovered for Low Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca’s jointly discovered ENHERTU® (fam-trastuzumab deruxtecan-nxki) breakthrough therapy for the treatment of patients with HER2 low metastatic breast cancer. ENHERTU is an engineered HER2 directed antibody drug conjugate (ADC). ENHERTU® has been developed for adult patients with unresectable...

Breakthrough CMS I-neb® Therapy Discovered for Non-Cystic Fibrosis Bronchiectasis (NCFB)

Zambon discovered new CMS I-neb® therapy for the treatment of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB). Colistimethate sodium powder for nebulization solution (CMS I-neb®) is a unique investigational treatment developed as potential first-in-class inhaled therapy...

Pfizer Inc. Discovered Breakthrough Respiratory Syncytial Virus (RSV)

Pfizer Inc, discovered breakthrough respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF for the treatment of lower respiratory tract illness in infants from birth up to age of six months by active immunisation of pregnant women. Once approved, the vaccine has the potential...

First-of-its-Kind SOBA-AD, Blood Test Developed to Detect Alzheimer’s Disease

AltPep Corporation developed first-of-its-kind SOBA-AD assay, a simple blood test for the detection of Alzheimer’s Disease. SOBA-AD assay is a blood test conducted to detect toxic oligomers which triggers rapid events associated with AD, such as cognitive impairment...

Breakthrough Monarch eTNS System® Discovered for Drug-Resistant Epilepsy (DRE)

NeuroSigma, discovered breakthrough Monarch eTNS System® Drug-Resistant Epilepsy (DRE). Monarch eTNS System® is designed for individuals with 18 years of age or older to lower the frequency of seizures diagnosed with epilepsy specified by partial-onset seizures, with or without secondary generalization, that are refractory to two or more antiepileptic medications....

Novel Mavacamten Discovered to Treat Obstructive Hypertrophic Cardiomyopathy (oHCM)

LianBio, discovered novel Mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin which is under investigation for the treatment of excessive cardiac contractility. It lowers the risk of cardiac muscle contractility by restricting...

First-of-its-Kind Digital Therapeutic BNT200 Discovered

Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy. BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive...

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA SGS - ADVANCED ANALYTICS Adare Pharma Solutions - Pediatric Formulation Solutions Thermo Fisher Scientific - 60th year celebration of The Gibco brand Clarivate Pharmavision 2022 Thermo Fisher Scientific - LC-MS biopharmaceutical applications